PMID- 26094583
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20211203
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 29
IP  - 7
DP  - 2015 Jul
TI  - Mammalian target of rapamycin inhibition after solid organ transplantation: can 
      it, and does it, reduce cancer risk?
PG  - 654-63
LID - 10.1111/ctr.12559 [doi]
AB  - The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has 
      been increasingly used as immunosuppressants for recipients of solid organ 
      transplants. Over the years, potential advantages unique to this class of 
      immunosuppressants have been recognized, including chemoprevention by virtue of 
      their antiproliferative effects. Prevention of malignancy after transplant 
      through mTOR inhibitor-based immunosuppression may have a specific practical 
      application in transplant recipients with preexisting malignancy including 
      hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the 
      biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support 
      a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent 
      or de novo, after solid organ transplantation in selected patients.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bhat, Mamatha
AU  - Bhat M
AD  - Division of Gastroenterology and Hepatology, McGill University Health Centre, 
      Montreal, QC, Canada.
FAU - Watt, Kymberly D
AU  - Watt KD
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150610
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Graft Rejection/etiology/*prevention & control
MH  - Graft Survival
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Neoplasms/etiology/*prevention & control
MH  - *Organ Transplantation
MH  - *Postoperative Complications
MH  - Prognosis
MH  - Risk Factors
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
OTO - NOTNLM
OT  - everolimus
OT  - immunosuppression
OT  - malignancy
OT  - mammalian target of rapamycin inhibitor
OT  - sirolimus
OT  - transplant
EDAT- 2015/06/23 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/06/23 06:00
PHST- 2015/04/30 00:00 [accepted]
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 10.1111/ctr.12559 [doi]
PST - ppublish
SO  - Clin Transplant. 2015 Jul;29(7):654-63. doi: 10.1111/ctr.12559. Epub 2015 Jun 10.